Pediatric Urology Unit, Division of Urology, Hospital Municipal Infantil Menino Jesus, São Paulo, Brazil.
Pediatric Urology Unit, Division of Urology, Hospital Municipal Infantil Menino Jesus, São Paulo, Brazil.
J Pediatr Urol. 2023 Jun;19(3):241-246. doi: 10.1016/j.jpurol.2023.01.004. Epub 2023 Jan 11.
Monosymptomatic enuresis (MNE) results from a pathogenic triad that may include lack of vasopressin secretion during sleep, reduced functional bladder capacity and inability to wake up during sleep. The treatment of MNE can be performed through behavioral therapy, use of alarms or medications such as desmopressin and imipramine.
To compare the effectiveness of different treatments of MNE.
Prospective and randomized study comparing different intervention and a control group (receiving only behavior therapy) for MNE.
age between 5 and 16 years old, with MNE, evaluated at the pediatric urology outpatient clinic of Hospital Infantil Menino Jesus. At first visit children were submitted to behavior therapy (urotherapy) for 3 months, children were subsequently characterized according to the ICCS as non-responders, partial responders, or full responders. Those partial responders or non-responders received a patient ID and were randomized to four groups: Alarm Group (G1), Desmopressin Group - DDAVP (G2), Imipramine Group (G3) and Control (G4). All groups were monitored monthly, for a period of 6 months. After 6 months, the children were reevaluated for MNE.
93 patients were enrolled. Mean age was 10.96 years with a standard deviation of 2.28 years, 59,1% were male. All groups had improvement in the number of dry nights (Table). Taking in account success the population full responders and partial responders: Alarm Group (G1) achieve success in 100% of cases, Desmopressin Group - DDAVP (G2) in 63.6% of cases, Imipramine Group (G3) in 73.7% of cases (Table 3). No drugs side effects were observed in both groups (G2 and G3), there was no dropout in patients who used alarms.
Our data suggests that the use of alarms is the most effective treatment of ENM with superior results when compared to imipramine and DDAVP. The small number of participants is a weakness of the study, as well as the lack of a voiding diary at the end of the study.
All therapeutics options utilized in the treatment of MNE are safe, effective and has a low rate of abandonment.
单症状性遗尿症(MNE)是由可能包括睡眠期间缺乏血管加压素分泌、功能性膀胱容量减少以及无法在睡眠中醒来的致病三联体引起的。MNE 的治疗可以通过行为疗法、使用警报器或药物(如去氨加压素和丙咪嗪)来进行。
比较 MNE 不同治疗方法的效果。
前瞻性随机研究,比较 MNE 的不同干预措施和对照组(仅接受行为疗法)。
年龄在 5 至 16 岁之间,患有 MNE,在 Hospital Infantil Menino Jesus 的小儿泌尿科门诊进行评估。初次就诊时,儿童接受行为疗法(尿动力学)治疗 3 个月,随后根据 ICCS 将儿童分为无反应者、部分反应者或完全反应者。那些部分反应者或无反应者将获得一个患者 ID,并随机分为四组:警报组(G1)、去氨加压素组 - DDAVP(G2)、丙咪嗪组(G3)和对照组(G4)。所有组均每月监测一次,持续 6 个月。6 个月后,对儿童进行 MNE 重新评估。
共纳入 93 名患者。平均年龄为 10.96 岁,标准差为 2.28 岁,59.1%为男性。所有组的夜间干燥夜数均有所改善(表)。考虑到完全和部分反应者的成功率:警报组(G1)的成功率为 100%,去氨加压素组 - DDAVP(G2)为 63.6%,丙咪嗪组(G3)为 73.7%(表 3)。在使用药物 G2 和 G3 的组中均未观察到药物副作用,使用警报器的患者中没有退出。
我们的数据表明,与丙咪嗪和 DDAVP 相比,使用警报器是治疗 MNE 最有效的方法,其效果更好。研究的弱点是参与者人数较少,以及研究结束时缺乏排尿日记。
MNE 治疗中使用的所有治疗选择都是安全、有效且退出率低的。